Cargando…

Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity

Human studies and preclinical models of Parkinson’s disease implicate the involvement of both the innate and adaptive immune systems in disease progression. Further, pro-inflammatory markers are highly enriched near neurons containing pathological forms of alpha synuclein (α-syn), and α-syn overexpr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benskey, Matthew J., Sellnow, Rhyomi C., Sandoval, Ivette M., Sortwell, Caryl E., Lipton, Jack W., Manfredsson, Fredric P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819572/ https://www.ncbi.nlm.nih.gov/pubmed/29497361 http://dx.doi.org/10.3389/fnmol.2018.00036

Ejemplares similares

Impact of age and vector construct on striatal and nigral transgene expression
por: Polinski, Nicole K, et al.
Publicado: (2016)

The contribution of alpha synuclein to neuronal survival and function – Implications for Parkinson's disease
por: Benskey, Matthew J., et al.
Publicado: (2016)

Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia
por: Sellnow, Rhyomi C., et al.
Publicado: (2019)

Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies
por: Sandoval, Ivette M., et al.
Publicado: (2021)

Loss of α-Synuclein Does Not Affect Mitochondrial Bioenergetics in Rodent Neurons
por: Pathak, Divya, et al.
Publicado: (2017)

Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS
por: Kanaan, Nicholas M., et al.
Publicado: (2017)

Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia
por: Steece‐Collier, Kathy, et al.
Publicado: (2019)

Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
por: Duffy, Megan F., et al.
Publicado: (2018)

Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
por: Duffy, Megan F., et al.
Publicado: (2018)

Microglial depletion does not impact alpha-synuclein aggregation or nigrostriatal degeneration in the rat preformed fibril model
por: Stoll, Anna C., et al.
Publicado: (2023)

Is Alpha-Synuclein Loss-of-Function a Contributor to Parkinsonian Pathology? Evidence from Non-human Primates
por: Collier, Timothy J., et al.
Publicado: (2016)

Loss of Functional Alpha-Synuclein: A Toxic Event in Parkinson’s Disease?
por: Kanaan, Nicholas M., et al.
Publicado: (2012)

Morphological and Behavioral Impact of AAV2/5-Mediated Overexpression of Human Wildtype Alpha-Synuclein in the Rat Nigrostriatal System
por: Gombash, Sara E., et al.
Publicado: (2013)

Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration
por: Van Rompuy, Anne-Sophie, et al.
Publicado: (2015)

Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression
por: Fischer, D. Luke, et al.
Publicado: (2017)

Downregulation of striatal Ca(V)1.3 inhibits the escalation of levodopa-induced dyskinesia in male and female parkinsonian rats of advanced age
por: Caulfield, Margaret E., et al.
Publicado: (2023)

High-Frequency Stimulation of the Rat Entopeduncular Nucleus Does Not Provide Functional or Morphological Neuroprotection from 6-Hydroxydopamine
por: Fischer, D. Luke, et al.
Publicado: (2015)

Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons
por: Benner, Eric J., et al.
Publicado: (2008)

The Nigral Coup in Parkinson’s Disease by α-Synuclein and Its Associated Rebels
por: Sian-Hulsmann, Jeswinder, et al.
Publicado: (2021)

The Longitudinal Transcriptomic Response of the Substantia Nigra to Intrastriatal 6-Hydroxydopamine Reveals Significant Upregulation of Regeneration-Associated Genes
por: Kanaan, Nicholas M., et al.
Publicado: (2015)

The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice
por: Migdalska-Richards, Anna, et al.
Publicado: (2017)

The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats
por: Mercado, Natosha M., et al.
Publicado: (2020)

Nicotine-Mediated Recruitment of GABAergic Neurons to a Dopaminergic Phenotype Attenuates Motor Deficits in an Alpha-Synuclein Parkinson’s Model
por: Lai, Jessica IChi, et al.
Publicado: (2023)

Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
por: Duffy, Megan F., et al.
Publicado: (2018)

Alpha-synuclein stimulation of astrocytes: Potential role for neuroinflammation and neuroprotection
por: Lee, He-Jin, et al.
Publicado: (2010)

PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein
por: Ciron, Carine, et al.
Publicado: (2015)

Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease
por: Maraganore, Demetrius M.
Publicado: (2011)

Sequential or Simultaneous Injection of Preformed Fibrils and AAV Overexpression of Alpha-Synuclein Are Equipotent in Producing Relevant Pathology and Behavioral Deficits
por: Negrini, Matilde, et al.
Publicado: (2022)

In vivo silencing of alpha-synuclein using naked siRNA
por: Lewis, Jada, et al.
Publicado: (2008)

Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson’s Disease in Rodents
por: Polinski, Nicole K., et al.
Publicado: (2018)

Dopaminergic Positron Emission Tomography Imaging in the Alpha‐Synuclein Preformed Fibril Model Reveals Similarities to Early Parkinson's Disease
por: Sossi, Vesna, et al.
Publicado: (2022)

Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson’s Disease
por: Zella, Maria Angela Samis, et al.
Publicado: (2019)

Alpha-synuclein–mediated DNA damage, STING activation, and neuroinflammation in Parkinson’s disease
por: Standaert, David G., et al.
Publicado: (2022)

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
por: Cole, Tracy A., et al.
Publicado: (2021)

Characterisation of functional deficits induced by AAV overexpression of alpha-synuclein in rats
por: Gubinelli, F., et al.
Publicado: (2022)

Chronic nigral neuromodulation aggravates behavioral deficits and synaptic changes in an α-synuclein based rat model for Parkinson’s disease
por: Torre-Muruzabal, Teresa, et al.
Publicado: (2019)

Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synuclein
por: Bentea, Eduard, et al.
Publicado: (2015)

Toxicity of extracellular alpha-synuclein is independent of intracellular alpha-synuclein
por: Dening, Yanina, et al.
Publicado: (2022)

Targeted Gene Delivery to the Enteric Nervous System Using AAV: A Comparison Across Serotypes and Capsid Mutants
por: Benskey, Matthew J, et al.
Publicado: (2015)

SUMOylation of Alpha-Synuclein Influences on Alpha-Synuclein Aggregation Induced by Methamphetamine
por: Zhu, Lin-nan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fros3giqvlopes5usuqct2j809